Company Overview - The company in focus is Fengbei Biological (603334), which specializes in the comprehensive utilization of waste resources, particularly known for its "waste oil refining" business model, converting waste oils into biodiesel and bio-based materials [3][5] - Fengbei Biological holds EU ISCC certification and has established partnerships with leading agricultural companies and international firms like Shell and BP, positioning itself as a top player in the domestic biodiesel industry [3] Financial Performance - From 2022 to 2024, the company's revenue is projected to increase from 1.709 billion to 1.949 billion yuan, while the net profit attributable to shareholders is expected to decline from 133 million to 124 million yuan, indicating a "revenue growth without profit growth" scenario [5] - The Q3 2025 report shows revenue of 2.251 billion yuan and a net profit of 117 million yuan, reflecting year-on-year growth of 62.32% and 35.32% respectively, but the net profit margin has decreased from 6.97% in the first half of 2024 to 5.21% [5] Market Reaction - After its debut on November 5, the stock experienced a significant drop, with seven out of nine trading days closing lower, plummeting from a peak of 76 yuan to around 47 yuan, highlighting a volatile market response [11][13] - The stock initially surged by 172% on the first day but faced a sharp decline of 14.4% the following day, leading to substantial losses for investors who bought in at higher prices [11][13] Investor Sentiment - Investors expressed frustration over the perceived manipulation of the stock, with claims that the actual controller had already profited through related transactions and cash dividends prior to the IPO, totaling over 65 million yuan [9] - The situation has raised concerns about the role of the underwriting institution, which is seen as prioritizing profit over the quality of the offering, leading to a sentiment of betrayal among retail investors [9][13]

Core Viewpoint - The rapid decline of Fengbei Bio's stock price by nearly 30% within three days of its IPO raises concerns about the company's financial health and governance, particularly as the actual controller has already cashed out over 65 million yuan before the stock plunge [3][7]. Financial Performance - Fengbei Bio's revenue increased from 1.709 billion yuan in 2022 to 1.949 billion yuan in 2024, but net profit attributable to shareholders decreased from 133 million yuan to 124 million yuan, marking two consecutive years of negative growth [3]. - The company's cash flow from operating activities plummeted by 86.2%, from 162 million yuan in 2023 to 22.43 million yuan in 2024, and further deteriorated to -7.5 million yuan in the first half of 2025 [4][5]. Profitability Issues - The gross profit margin has been declining sharply, from 13.95% in 2023 to 9.50% in the first half of 2025, primarily due to an increase in the sales proportion of low-margin industrial-grade mixed oil [5][7]. Trade Barriers Impact - The imposition of a 23.7% anti-dumping tax by the EU in July 2024 led to a drastic reduction in exports, with export revenue dropping from 434 million yuan in 2023 to 50.51 million yuan in 2024, a decline of over 85% [7]. - The average selling price of biofuels decreased by 25.51% from 9,800 yuan per ton in 2022 to 7,300 yuan per ton in 2024, alongside significant price drops in bio-based materials and chemical oils [7]. Expansion Strategy Concerns - Despite a decline in capacity utilization from 99.84% in 2023 to 76.31% in 2024, Fengbei Bio plans to raise 750 million yuan for capacity expansion projects, which may lead to increased depreciation and amortization costs of approximately 58 million yuan annually [8]. - The company's expansion strategy is risky as it heavily relies on market demand, which is currently showing signs of oversupply [8]. Regulatory and Compliance Issues - Fengbei Bio's subsidiaries have faced multiple environmental compliance issues, being listed as key pollutant units and ordered to rectify environmental problems [10]. - There are ongoing legal issues related to a fire incident causing significant inventory loss, and past actions involving questionable financial practices raise concerns about regulatory compliance [10][13]. Market Sentiment and Risks - Historical data indicates that new stocks with a first-day increase of over 150% have a high likelihood of declining in the following months, with an average drop of 27% after one month and 28% after three months [12]. - The company's IPO has become a cautionary tale for investors regarding the risks associated with speculative trading in newly listed stocks [13].